🚨Just out @CCR_AACR 🚨 V proud of our manuscript on polatuzumab efficacy by cell of origin in DLBCL We show COO by Hans predicts pola sensitivity in 740 pts Pts w R/R non-GCB DLBCL have higher ORR, CRR & PFS Massive thanks @dgermain21 & collabs! https://t.co/kGyRneMAuo

📣#ESHCLL2026: PRELIMINARY SCIENTIFIC PROGRAMME NOW LIVE! ➡️ https://t.co/yyuD5rfxm7 4th Translational Research Conference on Chronic Lymphocytic Leukaemia March 5–7, 2026 / Stockholm, Sweden Chairs : Jennifer Brown Paolo Ghia, @HallekMichael #ESHCONFERENCES #CLLsm #Lmsm

Grateful to be here in lovely Freiburg, Germany for the 5th International Liquid Biopsy Symposium, organized by my good friend @FSchererMD at the University of Freiberg! @max_diehn will be giving the Keynote. I’ll be presenting our work on urine cell-free nucleic acids tmrw.

Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma | Journal of Clinical Oncology https://t.co/jmQh4QsR3n Read this paper which shows that ctDNA MRD by PhasED-Seq is the most precise way to define a remission after therapy for LBCL.

https://t.co/N8W9Gkv9eR

Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study | Journal of Clinical Oncology

🎯 Time to register for the 5th International Liquid Biopsy Symposium in Freiburg, Germany — Sept 19–20, 2025! 🌍 Join us on-site or virtually 🧬 Amazing lineup of speakers 📢 Abstract submission now open! 🔗 Register:

Our very own CMO and co-founder, David Kurtz, was featured on the #ASCODailyNews discussing the incorporation of #ctDNA-MRD in NCCN Guidelines for B-cell Lymphoma. Read the article here: https://t.co/FeVsaschUR #PrecisionMedicine #ctDNA #Diagnostics #MRD @ASCO

Excited to share our study describing a new liquid biopsy method called RARE-Seq for analyzing cell-free RNA (#cfRNA) that is out today in @Nature. 1/15

We are very thankful for the great collaborations and support of all co-authors including @JurikMutter @StefanAlig @max_diehn @AshAlizadeh @LizSchorb and the support by @EKFStiftung @dfg_public @CRIIONorg @dgimev @DKTK_ @JCLStiftung

https://t.co/xVuQ4v60Ns.

Super happy to share our paper just published in @LeukemiaJnl, in which we demonstrate that minimal-invasive CNS lymphoma identification by ctDNA profiling in CSF can guide treatment and surgical management in daily clinical practice and large patient cohorts.

Die #EKFS Publikationspreise 2024 gehen an: 🔹Prof. Dr. Frederik Damm 🔹PD Dr. Florian Scherer (@FSchererMD) 🔹Dr. Ria Schönauer 🔹Dr. Dr. Lukas Bunse (@L_Bunse) 🔹PD Dr. Roman Sankowski (@r_sankowski) https://t.co/r0P1SUNI5d

Please RT and register: West German Lymphoma Symposium ⁦@HamatologieUk⁩ ⁦⁦@UniklinikEssen ⁦@MedEssen ⁦@unidue⁩ @dgho_eV⁩ #sfb1530

https://t.co/JEHHSXf8kU

Parallel to a great poster presentation by Dr. Miriam Mozaffari at #ASH2023, our new study was published in @BloodCancerJnl: Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure

The study was supported by @EKFStiftung, @dfg_public, @CRIIONorg, @Krebshilfe_Bonn, @dgimev, Foerdergesellschaft Forschung Tumorbiologie Freiburg.

Very thankful for the great collaboration between Dept. of Stereotactic Neurosurgery, Neuroradiology, Radiology, and Hem/Onc @Uniklinik_Fr (esp. E. Lauer and P. Reinacher) and with co-authors incl. @AshAlizadeh @LizSchorb, @StefanAlig, @JurikMutter, @GeraldIllerhaus, @max_diehn.

Finally, we leveraged 3D MRI volumetry and ctDNA detection (PhasED-Seq) to build a composite metric for outcome prediction at the earliest possible time point at diagnosis, which allowed the identification of patients with particularly favorable and unfavorable PFS and OS.

We found that patients showing a >97% 3D tumor volume reduction in the first interim MRI (= 3D early response, 3D_ER) had significantly favorable outcomes compared to those who did not achieve 3D_ER, both in log-rank and multivariate regression analyses.